Cargando…
Oncogenic enhancer of zeste homolog 2 is an actionable target in patients with non‐small cell lung cancer
BACKGROUND: The aims of this study were to investigate the link between enhancer of zeste homolog 2 (EZH2) and histone deacetylase (HDAC) in preclinical studies and in human lung cancer tissue microarrays. METHODS: Enhancer of zeste homolog 2 and HDAC1 mRNA expression in two lung adenocarcinoma (LUA...
Autores principales: | Shi, Bin, Behrens, Carmen, Vaghani, Viralkumar, Riquelme, Erick Marcelo, Rodriguez‐Canales, Jaime, Kadara, Humam, Lin, Heather, Lee, Jack, Liu, Hui, Wistuba, Ignacio, Simon, George |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6797579/ https://www.ncbi.nlm.nih.gov/pubmed/31456359 http://dx.doi.org/10.1002/cam4.1855 |
Ejemplares similares
-
Statins inhibit tumor progression via an enhancer of zeste homolog 2-mediated epigenetic alteration in colorectal cancer
por: Ishikawa, S, et al.
Publicado: (2014) -
Oncogenic roles of enhancer of zeste homolog 1/2 in hematological malignancies
por: Nakagawa, Makoto, et al.
Publicado: (2018) -
LAPTM4B is associated with poor prognosis in NSCLC and promotes the NRF2-mediated stress response pathway in lung cancer cells
por: Maki, Yuho, et al.
Publicado: (2015) -
Muscle RAS oncogene homolog (MRAS) recurrent mutation in Borrmann type IV gastric cancer
por: Yasumoto, Makiko, et al.
Publicado: (2016) -
The Arabidopsis homologs of trithorax (ATX1) and enhancer of zeste (CLF) establish ‘bivalent chromatin marks’ at the silent AGAMOUS locus
por: Saleh, Abdelaty, et al.
Publicado: (2007)